Poor
Not Aligned
Patient Risk:
Moderate
Summary
Core pharmacologic mechanism claims are supported by the provided label text, but the majority of additional claims (appetite/cravings/weight gain and insulin/leptin/ghrelin and insulin-resistance mechanisms, plus external source assertions) are not supported by the provided FDA-approved labeling excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that belongs to the HMG-CoA reductase inhibitor class.
Supported by 11 Description and 12.1 Mechanism of Action.
Lipitor works by blocking the production of cholesterol in the liver.
Supported by 11 Description and 12.1 Mechanism of Action (inhibits HMG-CoA reductase/cholesterol synthesis in the liver).
Lipitor reduces low-density lipoprotein (LDL) cholesterol levels in the blood.
Supported by 12.1 Mechanism of Action (reduces LDL-C).
Unsupported Statements
Some users report experiencing changes in appetite and cravings while taking Lipitor.
Not supported by the provided label sections (no appetite/cravings/weight-gain patient report content in supplied excerpts).
Changes in appetite and cravings reported with Lipitor can include increased hunger.
Not supported by the provided label sections.
Changes in appetite and cravings reported with Lipitor can include food cravings.
Not supported by the provided label sections.
Changes in appetite and cravings reported with Lipitor can include weight gain.
Not supported by the provided label sections.
Lipitor has been shown to affect levels of various hormones, including insulin, leptin, and ghrelin.
Not supported by the provided label sections.
Insulin resistance is a condition in which the body becomes less responsive to insulin.
General definition not supported by provided label sections.
Lipitor has been linked to insulin resistance.
Not supported by the provided label sections.
Insulin resistance can lead to increased hunger and cravings for carbohydrates.
Mechanistic claim not supported by provided label sections.
Leptin suppresses appetite.
General physiology statement not supported by provided label sections.
Ghrelin stimulates appetite.
General physiology statement not supported by provided label sections.
Lipitor has been shown to affect leptin and ghrelin levels.
Not supported by the provided label sections.
A study published in the Journal of Clinical Lipidology found that patients taking Lipitor experienced significant weight gain compared to those taking a placebo.
Not supported by the provided FDA-approved label excerpts.
The Journal of Clinical Lipidology study suggested that the weight gain with Lipitor was due to increased hunger and cravings rather than changes in physical activity or diet.
Not supported by the provided FDA-approved label excerpts.
Dr. David Jenkins stated that Lipitor can affect hunger and cravings by altering levels of hormones that regulate appetite.
Not supported by the provided FDA-approved label excerpts and relies on an external, non-label source.
Dr. David Jenkins stated that this can lead to increased hunger and food cravings, particularly for carbohydrates.
Not supported by the provided FDA-approved label excerpts and relies on an external, non-label source.
DrugPatentWatch.com notes that Lipitor has been associated with weight gain and changes in appetite in some users.
Not supported by the provided FDA-approved label excerpts and relies on an external, non-label source.
Lipitor can affect hormone levels, including insulin, leptin, and ghrelin, which may contribute to changes in appetite and cravings.
Not supported by the provided label sections.
Insulin resistance is a potential mechanism behind Lipitor-induced cravings.
Not supported by the provided label sections.
Leptin and ghrelin play a crucial role in regulating appetite and metabolism.
General physiology/mechanism not supported by provided label sections.
Lipitor's impact on leptin and ghrelin may lead to changes in cravings.
Not supported by the provided label sections.
Weight gain and changes in appetite have been reported in some users taking Lipitor.
Not supported by the provided label sections.
Some users have reported weight gain while taking Lipitor.
Not supported by the provided label sections.
Lipitor has been shown to affect levels of insulin, leptin, and ghrelin, which regulate appetite and metabolism.
Not supported by the provided label sections.
Lipitor has been linked to insulin resistance, which can lead to increased hunger and cravings for carbohydrates.
Not supported by the provided label sections.
Lipitor has been shown to affect levels of leptin and ghrelin.
Not supported by the provided label sections.
Contradictions
Important Omissions
FDA label-supported safety/adverse reaction content relevant to appetite/weight change (e.g., whether such effects are listed as adverse reactions or under warnings/precautions) was not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response adds multiple appetite/craving/weight-gain and hormone/insulin-resistance mechanistic claims that are not supported by the provided FDA label excerpts; while these do not directly establish a contraindication or boxed warning, they could mislead about clinically relevant effects.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous claims (appetite/cravings/weight gain, hormone effects, insulin/leptin/ghrelin mechanisms, and external study/quote assertions) are absent from the provided FDA-approved label sections.
Suggested Improvement
Limit statements to label-supported mechanism descriptions from the provided sections (e.g., HMG-CoA reductase inhibition, cholesterol synthesis inhibition in liver, LDL-C reduction). Remove or clearly qualify claims that are not supported by the supplied FDA label excerpts, including external-source attributions.